Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Currently unlisted.
Proposed listing date: 11:00AM 22 SEPTEMBER 2017
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| N27 | Ann: Appendix 3B - Share Purchase Plan Shares | 24/04/18 | 2 | 183 | |||
|
|||||||
| N27 | Ann: Junior Minerals Exploration Incentive | 24/04/18 | 0 | 106 | |||
|
|||||||
| N27 | Ann: Change of Director's Interest Notice - L Dean | 24/04/18 | 0 | 73 | |||
|
|||||||
| N27 | Ann: Change of Director's Interest Notice - M Schwarz | 24/04/18 | 0 | 57 | |||
|
|||||||
| N27 | Ann: Quarterly Activities and Cashflow Report 31 March 2018 | 22/04/18 | 6 | 1.2K | |||
|
|||||||
| N27 | Ann: Stanton Resource Upgrade Increases Contained Cobalt | 19/04/18 | 13 | 3.6K | |||
|
|||||||
| N27 | Ann: SPP Extension Pending Updated Mineral Resource | 18/04/18 | 8 | 2.6K | |||
|
|||||||
| N27 | Resistance @ 47c | 03/04/18 | 13 | 4.7K | |||
|
|||||||
See All Discussions
ASX News